Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the Literature.
COVID-19
Melanoma
anti-PD-1
cancer
Journal
Cancer investigation
ISSN: 1532-4192
Titre abrégé: Cancer Invest
Pays: England
ID NLM: 8307154
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
pubmed:
31
10
2020
medline:
26
1
2021
entrez:
30
10
2020
Statut:
ppublish
Résumé
The outbreak of COVID-19 pandemia is a major health worldwide concern. Patients with cancer might have a worse outcome, because of the immunosuppression determined by the tumor itself and anti-cancer treatments, including chemotherapy and radiotherapy. The impact and course of viral infection in patients receiving immunotherapy remains unknown. We report the case of a patient with metastatic melanoma, long responder to anti PD-1 blockade who got infected with Sars CoV-2, recovering without sequelae. A critical review of literature was performed. Limited data available in literature support the possibility to continue the immunotherapy in patients with cancer under control.
Identifiants
pubmed: 33125301
doi: 10.1080/07357907.2020.1844893
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
Immune Checkpoint Inhibitors
0
pembrolizumab
DPT0O3T46P
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM